Terminated/Withdrawn
Sponsor ID
20101145
Etanercept Treatment in Patients with Moderate to Severe Plaque Psoriasis who Lost Response to Adalimumab
Study Details
This study will evaluate the efficacy of etanercept in patients with plaque psoriasis who have lost a satisfactory response to adalimumab.
Protocol Summary
Primary Outcome Measures
Efficacy of etanercept
Timeframe: 12 Weeks
Secondary Outcome Measures
Safety of etanercept
Timeframe: 24 Weeks
Evaluate and compare efficacy and safety in subjects with and without antibodies to adalimumab
Timeframe: All Visits (Weeks 4, 8, 12, 16, 20 and 24)
Effect of treatment with etanercept on patient reported outcomes
Timeframe: 12 and 24 Weeks
Effect of treatment with etanercept on patient reported outcomes
Timeframe: 12 and 24 Weeks
Effect of treatment with etanercept on patient reported outcomes
Timeframe: 12 and 24 Weeks
Effect of treatment with etanercept on patient reported outcomes
Timeframe: 12 and 24 Weeks
Study Documents
Study Synopsis
Available Language(s): English
Locations
Location
Research Site
Los Angeles, CA, United States, 90045
Status
Completed
Location
Research Site
Macon, GA, United States, 31217
Status
Completed
Location
Research Site
Atlanta, GA, United States, 30342
Status
Completed
Location
Research Site
Birmingham, AL, United States, 35205
Status
Completed
Location
Research Site
Denver, CO, United States, 80220
Status
Completed
Location
Research Site
East Windsor, NJ, United States, 08520
Status
Completed
Showing {first} - {last} of {total} Results